Evotec (NASDAQ:EVO - Get Free Report) is set to announce its earnings results before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.
Evotec Stock Down 2.3 %
Shares of EVO stock traded down $0.09 during trading on Thursday, reaching $3.87. The company's stock had a trading volume of 53,250 shares, compared to its average volume of 106,056. The business has a fifty day moving average price of $3.43 and a 200-day moving average price of $4.36. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.73 and a current ratio of 1.83. Evotec has a one year low of $2.85 and a one year high of $12.00.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on EVO shares. Morgan Stanley lowered shares of Evotec from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $15.00 to $6.00 in a research report on Monday, July 29th. Jefferies Financial Group lowered shares of Evotec from a "buy" rating to a "hold" rating and dropped their price target for the stock from $8.70 to $3.80 in a research report on Monday, October 7th. Deutsche Bank Aktiengesellschaft lowered shares of Evotec from a "hold" rating to a "sell" rating in a research report on Thursday, August 8th. Finally, HC Wainwright dropped their price target on shares of Evotec from $11.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $5.93.
Check Out Our Latest Report on EVO
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
